Engineering Iron Oxide Nanoparticles for Clinical Settings
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Iron oxide nanoparticles (IONPs) occupy a privileged position among magnetic nanomaterials with potential applications in medicine and biology. They have been widely used in preclinical experiments for imaging contrast enhancement, magnetic resonance, immunoassays, cell tracking, tissue repair, magnetic hyperthermia and drug delivery. Despite these promising results, their successful translation into a clinical setting is strongly dependent upon their physicochemical properties, toxicity and functionalization possibilities. Currently, IONPs-based medical applications are limited to the use of non-functionalized IONPs smaller than 100 nm, with overall narrow particle size distribution, so that the particles have uniform physical and chemical properties. However, the main entry of IONPs into the scene of medical application will surely arise from their functionalization possibilities that will provide them with the capacity to target specific cells within the body, and hence to play a role in the development of specific therapies. In this review, we offer an overview of their basic physicochemical design parameters, giving an account of the progress made in their functionalization and current clinical applications. We place special emphasis on past and present clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Numerous research groups are interested in the functionalization of IONPs with trastuzumab, a commercial and approved antibody for breast cancer treatment [41], for the development of targeted therapeutic strategies.”
BackgroundNoninvasive detection of clinically occult lymph-node metastases in prostate cancer
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., & Weissleder, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022749 · Cited by 1,971
Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION)
Singh, N., Jenkins, G. J. S., Asadi, R., & Doak, S. H. (2010) · Nano Reviews · doi:10.3402/nano.v1i0.5358 · Cited by 1,112
de Vries, I. J. M., Lesterhuis, W. J., Barentsz, J. O., Verdijk, P., van Krieken, J. H., Boerman, O. C., Oyen, W. J. G., Bonenkamp, J. J., Boezeman, J. B., Adema, G. J., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1154 · Cited by 821 · cited 1×
“investigated the biodistribution of SPION-labelled DCs applied as cancer vaccines in melanoma patients using MRI, and demonstrated that MRI allowed assessment of the accuracy of DC delivery and of inter- and intranodal cell migration patterns [104].”
BackgroundImaging macrophages with nanoparticles
Weissleder, R., Nahrendorf, M., & Pittet, M. J. (2014) · Nature Materials · doi:10.1038/nmat3780 · Cited by 809 · cited 1×
“This figure was reproduced with permission from Nature Materials [126].”
MethodYu, M., Huang, S., Yu, K. J., & Clyne, A. M. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13055554 · Cited by 308
Heesakkers, R. A., Hövels, A. M., Jager, G. J., van den Bosch, H. C., Witjes, J. A., Raat, H. P., Severens, J. L., Adang, E. M., van der Kaa, C. H., Fütterer, J. J., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70203-1 · Cited by 307 · cited 1×
“From this point of departure, a number of clinical trials have successfully tested the IONP-enhanced MRI to detect sentinel lymph nodes in prostate cancer [93][94], as well as other types of cancers like bladder [95], breast (Endorem [96] and Resovist [97][98]) and renal cell (Sinerem) [99], among others (Table 4).”
BackgroundNoninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients
Gaglia, J. L., Guimaraes, A. R., Harisinghani, M., Turvey, S. E., Jackson, R., Benoist, C., Mathis, D., & Weissleder, R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44339 · Cited by 209 · cited 1×
“Using ferumoxtran, a significant improvement was observed in a small cohort of Type 1A diabetes patients (NCT00585936) in the diagnosis of pancreatic islet inflammation when compared to T1-gadolinium [82].”
BackgroundTourdias, T., Roggerone, S., Filippi, M., Kanagaki, M., Rovaris, M., Miller, D. H., Petry, K. G., Brochet, B., Pruvo, J.-P., Radüe, E.-W., et al. (2012) · Radiology · doi:10.1148/radiol.12111416 · Cited by 85
USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure
Sigovan, M., Gasper, W., Alley, H. F., Owens, C. D., & Saloner, D. (2012) · Radiology · doi:10.1148/radiol.12112694 · Cited by 55
Cited by
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Magnetic Nanoparticles in Cancer Theranostics
Gobbo, O. L., Sjaastad, K., Radomski, M. W., Volkov, Y., & Prina-Mello, A. (2015) · Theranostics · doi:10.7150/thno.11544 · Cited by 462
Yarjanli, Z., Ghaedi, K., Esmaeili, A., Rahgozar, S., & Zarrabi, A. (2017) · BMC Neuroscience · doi:10.1186/s12868-017-0369-9 · Cited by 296
Magnetic Resonance Imaging and Iron-oxide Nanoparticles in the era of Personalized Medicine
Rahman, M. (2023) · Nanotheranostics · doi:10.7150/ntno.86467 · Cited by 244
Askri, D., Ouni, S., Galai, S., Chovelon, B., Arnaud, J., Lehmann, S. G., Sakly, M., Sève, M., & Amara, S. (2018) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2018.06.006 · Cited by 11
Metadata
- Authors
- Cortajarena, A. L., Ortega, D., Ocampo, S. M., Gonzalez-García, A., Couleaud, P., Miranda, R., Belda-Iniesta, C., & Ayuso-Sacido, A.
- Venue
- Nanobiomedicine
- Publisher
- SAGE Publications
- Published
- 2014-01-01
- Volume
- 1
- Pages
- 2-2
- ISSN
- 1849-5435 (ISSN-L)
- OpenAlex
- W2037645193
- Cited by
- 149
- References
- 10
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.